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TO THE EDITOR
Small non-cleaved cell lymphomas (SNCL) as coined initially by Lukes and Collins and as used in the Working Formulation encompass Burkitt's lymphomas and non-Burkitt (Burkitt-like) lymphomas. The treatment of SNCLs involves combination chemotherapy consisting of intensive doses of alkylating agents (such as cyclophosphamide) given together with other agents including anthracyclines, vincristine, methotrexate and ara-C. With these regimens, overall survival rates of 80% to 90% have been reported. 1, 2 The cure rate for patients with mature B cell acute lymphoblastic leukemia, a closely related disorder, is in the range of 40-60%. 3 Patients with recurrent disease have a poor prognosis. A small number of these patients respond to salvage regimens followed by high-dose chemotherapy and autologous or allogeneic stem cell transplantation. Therefore, exploration of agents with alternative and specific modes of action, for example by targeting the protein product of the c-myc proto-oncogene, may provide us with more effective therapies.
Arsenic trioxide (As 2 O 3 ) is a trivalent inorganic arsenical used as a medicinal agent particularly in Central and Southern Asia. Recent studies have established the role of As 2 O 3 in the treatment of patients with relapsed acute promyelocytic leukemia. The exact mechanism of action of As 2 O 3 in this setting is not clear and may be diseasespecific. However, preclinical studies have suggested a broader antineoplastic activity including effects in myelodysplastic syndrome and solid tumor cell lines. More recently, activity of As 2 O 3 in lymphoid malignancies has been reported by a number of authors in in vitro studies. 4, 5 A synergistic effect between As 2 O 3 and ascorbic acid has been reported, suggesting a possible role for this combination in patients with acute myeloid leukemia. We investigated the usefulness of this combination in a patient with advanced, refractory Burkitt-like non-Hodgkin's lymphoma.
The patient, a 29-year-old female, presented with night sweats, weight loss of 30 lb over a 1-month period, back pain, and gastrointestinal symptoms with abdominal pain, nausea and vomiting. On clinical examination she was found to have a large abdominal mass with clinically evident pleural effusions, but with no palpable peripheral lymphadenopathy. Laboratory studies revealed an elevated LDH of 419 /l (normal range 90-180 /l), beta-2-microglobulin of 2.4, normal blood counts, and normal liver and renal function. On imaging studies she was noted to have marked lymphadenopathy involving the upper aortic, celiac, juxtadiaphragmatic, internal mammary, anterior mediastinal and paratracheal nodes. Marked thickening of the omentum throughout the upper abdomen, as well as a large 9 × 12 cm mesenteric mass were demonstrated. Other findings included bilateral pleural effusions and normal liver and spleen, as well as other intraabdominal structures. Biopsy of the omental mass revealed small to medium-sized cells suggestive of non-cleaved B cell lymphoma. Flow cytometry demonstrated a monoclonal B cell population with lambda light chain restriction and positive staining for CD10, CD20, CD19, CD38 and IgM. The specimen was positive for the bcl-2 gene rearrangement. 6 A diagnosis of Burkitt-like lymphoma was established. Bone marrow examination as well as examination of cerebrospinal fluid was negative for involvement by lymphoma. Therapy with the hyperCVAD regimen 3 was initiated and a repeat CT of abdomen after two cycles of treatment revealed a decrease in the size of the omental mass. However, with recurrence of symptoms after the third cycle of therapy, progression of the intra-abdominal disease was suspected and demonstrated by a repeat CT scan. A change of treatment to the combination of CHOP and rituximab was unsuccessful with further progression of disease and development of an 'omental cake', as well as enlarging intra-abdominal nodes and new lung nodules. In preparation for an autologous stem cell transplant, therapy with Plot of level of lactate dehydrogenase against time.
ifosfamide and etoposide was administered unsuccessfully 7 with demonstration of further progression of disease by imaging and a rapid rise in LDH (Figure 1 ). Combination therapy with As 2 O 3 (0.25 mg/m 2 intravenously over 2 h daily), as well as ascorbic acid (500 mg orally twice daily) was commenced and was continued daily for a period of 2 weeks. On day 10 of As 2 O 3 therapy, following an initial drop in serum LDH (Figure 1 ) and demonstration of disease stabilization by CT scan, prednisone 60 mg every 12 h for five doses was administered in an attempt to improve the response. After a period of 1 week off therapy, a further five doses of As 2 O 3 were administered before discontinuing treatment due to general debilitation. Side effects encountered during therapy with As 2 O 3 included mild nausea, fatigue, significant edema of lower extremities, asymptomatic prolongation of QT interval, and significant neutropenia requiring growth factor support. Following a 1-month period of stabilization as demonstrated by CT scan and after the patient had received a total of 19 days of the combination, therapy was discontinued due to the side-effects, as well as further disease progression. The patient did not receive any further therapy and succumbed to her disease.
Significant progress in the therapy of SNCLs of Burkitt and Burkittlike types has resulted in impressive response rates with current combination regimens. Unfortunately, treatment options for patients with relapsed or refractory disease remains limited with only occasional cures after allogeneic or autologous progenitor cell transplantation. New agents with novel mechanisms of action need to be explored in this setting, particularly in patients who are unable to undergo transplantation. Arsenic trioxide has demonstrated impressive activity in patients with relapsed APL and has recently been approved for this purpose. Preclinical studies have demonstrated activity of this agent in other malignancies including lymphoma. 4, 5 A preliminary report from China also indicates activity of arsenic compounds in NHL, 8 but such activity has to our knowledge not been confirmed in a prospective study in the West. We observed activity of this agent, in combination with ascorbic acid and steroids, in a patient with refractory Burkitt-like lymphoma, as indicated by transient stabilization of radiological findings and decrease in serum LDH. We propose further examination of this combination in patients with refractory aggressive lymphomas. This may allow possible roles for inclusion of the agent in earlier stages of the disease.
F Ravandi
The ) is an essential component in the diet of mammals, and its deficiency has been associated with enhanced susceptibility to cancer. 1 Zn ++ is found in more than 300 metalloenzymes, influencing gene expression by either structural stabilization or functional regulation of various transcription factors. However, the role of this metal ion in tumor development has not been yet elucidated.
We report here that addition of 100 M ZnSO 4 to cultures drastically inhibited c-Myc protein expression in different types of human leukemia cells, and that its activity was concentration-dependent (Figures 1a and 2a) . The inhibitory effect of Zn ++ on c-myc expression was not related to a pro-apoptotic effect, since the percentage of apoptotic cells as assessed by AnnexinV-FITC cell binding did not change in ZnSO 4 -treated cells, being Ͻ6% of total cells up to 24 h of treatment (data not shown). In contrast, the expression of either structurally or functionally related proteins Max and Tal-1 was not affected (Figure  2b and c) . Interestingly, we observed that Zn ++ reduced c-Myc protein levels also in Burkitt's lymphoma cells (Raji cell line). In these cells, c-Myc expression is increased in basal conditions as a consequence of a deregulated rate of transcription, but this effect was not present in VLL lymphoblastoid B line, where c-Myc enhanced expression is mainly due to increased mRNA stability (Figure 2d) . 2 Further study is needed to clarify this issue.
These findings were firstly observed using the Zn ++ sulfate salt. To extend our results to other Zn ++ salts, additional experiments were performed using zinc acetate ((CH 3 COO) 2 Zn) and zinc chloride (ZnCl 2 ). Both these zinc salts also elicited a significant inhibition of c-myc expression (Figure 1b) . To investigate the possible effect of other metal ions on c-Myc expression and to exclude any possible direct activity of the sulfate, acetate or chloride ions, the effect of different compounds including ferrous sulfate (FeSO 4 ), cadmium acetate ((CH 3 COO) 2 Cd), as well as several metal chloride salts including CdCl 2 , FeCl 3 , HgCl 2 , SrCl 2 and NiCl 2 was also investigated. None of these substances was found to inhibit c-Myc expression (Figure 1c  and d) . c-Myc is a transcription factor that plays a pivotal role in the regulation of cell growth, cell-cycle progression, apoptosis and terminal differentiation. 3 Therefore, perturbation of c-Myc levels is critical in influencing growth of malignant cells, and in particular in those of
